Tag
First person treated in a gene therapy trial using partial reprogramming to rejuvenate cells, aiming to treat glaucoma by regenerating optic nerve neurons.
New Limit's cellular reprogramming therapy, delivered via mRNA in lipid nanoparticles, restores liver resilience and improves survival in aged mice subjected to repeated alcohol cycles, with human trials planned next year in Australia.